Xevudy

Xevudy (sotrovimab) is a monoclonal antibody treatment for COVID-19 in high-risk adults and adolescents. Designed to reduce hospitalization risk, it targets the SARS-CoV-2 virus. This overview covers key details for informed use. Xevudy sotrovimab COVID-19 treatment overview for safe use.

Xevudy (sotrovimab) is used to treat mild-to-moderate COVID-19 in adults and adolescents who are at high risk of progressing to severe disease. It may help reduce the risk of hospitalization or severe outcomes when given early in infection. People often ask, what is Xevudy used for, and the answer is COVID-19 treatment for high-risk patients. It is not a substitute for vaccination but provides an option for those already infected.

Xevudy works by binding to the spike protein of the SARS-CoV-2 virus, helping the immune system recognize and neutralize the virus. Patients may experience relief from symptoms such as fever, cough, and fatigue as the treatment takes effect. Common effects include temporary improvement in breathing and energy levels during recovery. Most people tolerate it well without significant discomfort.

Xevudy should be administered under medical supervision by healthcare professionals in a clinical setting. Patients with known allergies to any component of the drug should avoid it. Pregnant or breastfeeding individuals should discuss risks with their doctor before use. Keep all follow-up appointments to monitor response and any potential reactions.

Limited data exist on drug interactions with Xevudy, but caution is advised when combining with other monoclonal antibodies or immunomodulators. No specific interactions with common medications like pain relievers or antibiotics have been reported. Always inform your healthcare provider about all medications you are taking to assess potential risks. Avoid alcohol during treatment to support recovery.